TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00948896
Drug: sulfadoxine-pyrimethamine (SP)
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: monthly dosing given as a single dose, 500mg/25mg tabs
Study: NCT00948896
Drug: dihydroartemisinin-piperaquine (DP)
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs
Study: NCT03601611
Drug: Tocilizumab (RoACTEMRA®)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prednisolon will be given in case of worsening of symptoms
Study: NCT03448458
Drug: Gallium Ga 68-DOTATATE
Normalized name: Gallium (Ga 68) dotatate
DrugBank: Gallium nitrate (DB05260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00943566
Drug: Sustained Release Morphine Sulfate
Normalized name: morphine Extended Release Oral Tablet
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained Release Morphine Sulfate tablets every 12 hours; up to 400 mg every day for 19 days (7 days of conversion to sustained release morphine sulfate and 12 days of observation)
Study: NCT01283061
Drug: Zafirlukast
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zafirlukast tablets 20 mg
Study: NCT04501874
Drug: EMB-001
Normalized name: EMB
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 720 mg metyrapone/24 mg oxazepam mg BID
Study: NCT01965600
Drug: PF-06282999
Normalized name: PF-06282999
DrugBank: PF-06282999 (DB11683)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 125 mg, TID, 3 days, 1 of 2 periods
Study: NCT01965600
Drug: PF-06282999
Normalized name: PF-06282999
DrugBank: PF-06282999 (DB11683)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 500 mg, BID, 3 days, 1 of 2 periods
Study: NCT00363272
Drug: ispinesib
Normalized name: Ispinesib
DrugBank: Ispinesib (DB06188)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04139057
Drug: EBV-specific TCR-T cell with anti-PD1 auto-secreted element
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with anti-PD1 auto-secreted element
Study: NCT01156636
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg 3 times/day for 1 year
Study: NCT00387621
Drug: Nesiritide
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The first 10 subjects in each group will receive a dose of 5 ug/kg and the next ten subjects will receive 10 ug/kg.
Study: NCT00387621
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
Study: NCT04516616
Drug: Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PD-1 monoclonal antibody （SHR-1210)：200mg，IV infusion，Q3W Cisplatin：75-80 mg/m2, IV infusion, Q3W Albumin-bound paclitaxel: 260 mg/m2，30min，IV infusion, Q3W
Study: NCT02924311
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Eylea 40 mg/mL - recommended dose of 2 mg - intravitreal injection monthly for five consecutive months, which constitutes the loading dose. The loading dose is followed by one injection every two months. After 12 months of treatment, the interval between two injections can be prolonged or adapted according to visual and anatomical results.
Study: NCT00208858
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04046029
Drug: Bivalirudin
Normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bivalirudin will be given as a bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion,a reduced-dose infusion (0.2 mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
Study: NCT01666301
Drug: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00412555
Drug: oseltamivir [Tamiflu]
DrugBank: Oseltamivir acid (DB02600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-75mg po daily for 6 weeks
Study: NCT02451137
Drug: Insulin glargine, 300 U/ml
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT02451137
Drug: Insulin glargine, 100 U/ml
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT02451137
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT01034345
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Switch from calcineurin inhibitor maintenance immunosuppression to sirolimus treatment at the doses needed to reach trough blood levels 8-15 ng/mL.
Study: NCT00000291
Drug: Labetalol
Normalized name: Labetalol
DrugBank: Labetalol (DB00598)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01977573
Drug: rhEPO
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locally sourced rhEPO. All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered..
Study: NCT03196401
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: durvalumab 1500mg administered intravenously every 28 days, for a total of six doses
Study: NCT00781001
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg placebo or active cannabis administered via the Volcano vaporizer 1x per study visit
Study: NCT06601205
Drug: Flutamide
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet daily until the day before surgery
Study: NCT06601205
Drug: Finasteride
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet daily until the day before surgery
Study: NCT03576807
Drug: CD20 CAR-T cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 1 - 20×10\^6 CD20 CAR-T cells/kg will be administered by IV infusions.
Study: NCT04300556
Drug: Farletuzumab ecteribulin
Normalized name: Farletuzumab ecteribulin
DrugBank: Farletuzumab ecteribulin (DB18857)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Farletuzumab ecteribulin intravenous infusion.
Study: NCT04300556
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone administered orally.
Study: NCT04300556
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone administered orally.
Study: NCT02980211
Drug: Alveolar Ridge Reconstruction
Normalized name: BLUE RIDGE BLUEBERRY
DrugBank: Blueberry (DB10629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconstruction of dehiscence defects in extraction sockets with a minimally invasive technique using a particulate bone allograft and a non-absorbable dense polytetrafluoroethylene (dPTFE) membrane
Study: NCT01200251
Drug: Bimatoprost eyelash gel
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost 0.03% solution was compounded into a gel - patients used on eyelash margin once daily placing gel with a fingertip or Q-tip for 6 months
Study: NCT00978705
Drug: Autologous cultured keratinocyte cell
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x10\^7 cell/ vial
Study: NCT00211198
Drug: ONTAK (denileukin difitox, DAB389IL-2)
Normalized name: denileukin diftitox Injection [Ontak]
DrugBank: Denileukin diftitox (DB00004)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04489511
Drug: STG-001
Normalized name: STG-001
DrugBank: STG-001 (DB16734)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1 or Dose 2 of STG-001 will be administered daily for 28 days to compare safety, pharmacokinetics and pharmacodynamics in Stargardt disease subjects.
Study: NCT04392531
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the experimental group, cyclosporine will be started according to patient weight, and then increased depending on patient tolerance (monitoring renal function and blood pressure)
Study: NCT00184730
Drug: somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02885506
Drug: Oral administration of P218 capsules
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.
Study: NCT01041027
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01041027
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03648021
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: \>50kg: Paracetamol 1 gramme in a solution of 10mg/mL administred intravenously. 1 dose~\>50kg: Paracetamol 15mg/kg/dose in a solution 10mg/mL administred intravenously. 1 dose
Study: NCT00001426
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00001426
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001426
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00042575
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00977600
Drug: Ammonul
Normalized name: Ammonul
DrugBank: Benzoic acid (DB03793)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00977600
Drug: Buphenyl
Normalized name: Buphenyl
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02335359
Drug: tranexamic acid diluted in 100 ml of saline solution (loading dose)
Normalized name: tranexamic acid 100 MG/ML
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02335359
Drug: tranexamic acid undiluted (continous infusion)
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03397966
Drug: recombinant human BNP(1-32)
Normalized name: BNP-32
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive an IV infusion of recombinant human BNP(1-32) for 240 minutes at a rate of 10 ng/kg/minute for 240 minutes, preceded by an IV bolus of 100 ng/kg.
Study: NCT03397966
Drug: placebo (control, normal saline)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive an IV infusion of placebo (normal saline) at a rate of 10 ng/kg/minute for 240 minutes, preceded by an IV bolus of 100 ng/kg.
Study: NCT01519700
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Eligible patients will be teated with Filgrastim
Study: NCT03606473
Drug: d-amphetamine
Normalized name: d-amphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: is used to stimulate dopamine release in the brain
Study: NCT00821600
Drug: risperidone IR and LAI formulation
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 mg risperidone IR single injection, followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
Study: NCT06514365
Drug: IPACK block with Bupivacaine 0.25% with adrenaline
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The iPACK in performed in the popliteal fossa about 1 finger breath above the patella, ecoguided. That aims to anesthetize the articular branches to the posterior aspect of the knee in the popliteal region.
Study: NCT04434937
Drug: parsaclisib
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: parsaclisib will be taken orally QD with water without regard to food except on mornings of PK clinic visits
Study: NCT03375788
Drug: Tesamorelin
Normalized name: Tesamorelin
DrugBank: Tesamorelin (DB08869)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tesamorelin F4 formulation 1.4mg daily
Study: NCT00267826
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusion of 1000mg Rituximab (anti-CD20) on days 1 and 15 to patients with atopic dermatitis
Study: NCT01358266
Drug: DE-109 44 ug
Normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose
Study: NCT01358266
Drug: DE-109 440 ug
Normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium dose
Study: NCT01358266
Drug: DE-109 880 ug
Normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High dose
Study: NCT00811590
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus is a novel derivative of rapamycin. Everolimus has been in clinical development since 1996 as an immunosuppressant in solid organ transplantation. Since 2003, RAD001 is approved in Europe (trade name: Certican) via the Mutual Recognition Procedure (MRP) for the prevention of organ rejection in patients with renal and cardiac transplantation. Certican is also approved in Australia, South Africa, the Middle East, Central and South America, the Caribbean and some Asian countries.~Everolimus is being investigated as an anticancer agent based on its potential to act~* directly on the tumor cells by inhibiting tumor cell growth and proliferation~* indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell VEGF production and VEGF-induced proliferation of endothelial cells.
Study: NCT03299166
Drug: Troriluzole
Normalized name: Troriluzole
DrugBank: Troriluzole (DB15079)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troriluzole, 140 mg capsules once daily (QD) orally for the first 4 weeks and 200 mg (140 mg+ 60 mg capsules QD) for an additional 8 weeks
Study: NCT04272086
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25%
Study: NCT04272086
Drug: Bupivacaine liposome
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mL
Study: NCT04084860
Drug: CI-581a
Normalized name: CI 77266
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-581a during weeks 1 and 6 at 0.71 mg/kg
Study: NCT04084860
Drug: CI-581b
Normalized name: CI 77266
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-581b during weeks 1 and 6 at 0.0125 mg/kg
Study: NCT01203202
Drug: Clomipramine
Normalized name: Clomipramine
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg and 30mg on demand
Study: NCT03527108
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The treatment will be given on a 28-day cycle, with doses of nivolumab and ramucirumab given on days 1 and 15. The dose of nivolumab will be fixed at 240 mg. Nivolumab should be administered first, followed by premedication, and then ramucirumab. Ramucirumab should be administered approximately 30 minutes after premedication
Study: NCT03527108
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The treatment will be given on a 28-day cycle, with doses of nivolumab and ramucirumab given on days 1 and 15. The dose of ramucirumab will depend upon the patient weight as noted below. Nivolumab should be administered first, followed by premedication, and then ramucirumab. Ramucirumab should be administered approximately 30 minutes after premedication
Study: NCT00873496
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01393652
Drug: PF-05105679
Normalized name: PF-05105679
DrugBank: PF-05105679 (DB15450)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
Study: NCT01393652
Drug: PF-05105679
Normalized name: PF-05105679
DrugBank: PF-05105679 (DB15450)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will be randomized to a treatment sequence, and assigned to placebo, 2 separate single doses of PF-05105679 in the fasted state and to controlled-release Oxycodone 20 mg (positive control) , with at least one week wash-out between doses.
Study: NCT03510546
Drug: Pyridostigmine
Normalized name: Pyridostigmine
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study dose as per protocol.
Study: NCT01100619
Drug: rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one 4 mg dose as a tablet followed by a second 4 mg dose 3 weeks later
Study: NCT01100619
Drug: XL184
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dosed with capsules daily
Study: NCT02739906
Drug: BioChaperone Human Insulin (HinsBet®)
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BioChaperone Human Insulin (HinsBet®) individualised single subcutaneous injection followed by test meal intake
Study: NCT02739906
Drug: Insulin Lispro (Humalog®)
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Lispro (Humalog®) individualised single subcutaneous injection followed by test meal intake
Study: NCT03857165
Drug: SAP-001
Normalized name: HURA CREPITANS SAP
DrugBank: AP-001 (DB18511)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAP-001 or placebo treatment in a 3:1 randomization ratio.
Study: NCT00185146
Drug: Pactimibe
Normalized name: Pactimibe
DrugBank: Pactimibe (DB12971)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00237302
Drug: topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02190695
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m2 by vein daily over 1 hour on Days 1-5 of each 28 day cycle.
Study: NCT02190695
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5 by vein over 1 hour on Day 8 of each 28 day cycle.
Study: NCT02190695
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.15 mg/kg by vein over 1 hour on Days 1-5 of each 28 day cycle.
Study: NCT00228267
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03742557
Drug: Ketamine 50 MG/ML Injectable Solution, 0.5 mg/kg IV
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine 0.5 mg/kg IV
Study: NCT01222689
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01222689
Drug: selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04379856
Drug: NM-002
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NM-002 is a fusion protein, of which the pharmacological active portion is the glucagon-like peptide-1 (GLP-1) analog domain with the same amino acid sequence as the active pharmaceutical ingredient (exenatide)
Study: NCT00648063
Drug: Letrozole Tablets 2.5 mg
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5mg, single dose fasting
Study: NCT01047358
Drug: Aromasin
Normalized name: Aromasin
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg table QD
Study: NCT00674817
Drug: 400 microgrammes GSK961081
Normalized name: Extramel microgranules
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled GSK961081 administered via Dry Powder Inhaler.
Study: NCT00674817
Drug: 1200 microgrammes GSK961081
Normalized name: Extramel microgranules
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled GSK961081 adminisntered via dry powder inhaler.
Study: NCT00887536
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bevacizumab 15 mg/kg IV every 21 days for 6 cycles followed by bevacizumab 15 mg/kg IV every 21 days until 1 year following the first dose of bevacizumab
Study: NCT00887536
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 75 mg/m2 IV every 21 days for 6 cycles
Study: NCT00887536
Drug: pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pegfilgrastim 6 mg subcutaneous (SC) Day 2 every 21 days for 6 cycles \[filgrastim (Neupogen®) 5 mcg/kg Days 2-10 may be given in lieu of pegfilgrastim (Neulasta®), but pegfilgrastim is preferred.\]